3.0.0 3335 2023-01-11T13:33:34Z 2023-01-11T13:33:34Z Senate S 2016-09-15 114 sshr00 Health, Education, Labor, and Pensions Committee Senate Standing Referred to 2016-09-15T15:23:25Z Fair Accountability and Innovative Research Drug Pricing Act of 2016 114 6043 HR 2016-09-15 Referred to the House Committee on Energy and Commerce. Identical bill CRS 2016-09-15 sshr00 Health, Education, Labor, and Pensions Committee Senate Read twice and referred to the Committee on Health, Education, Labor, and Pensions. IntroReferral 2016-09-15 Introduced in Senate IntroReferral 10000 9 Library of Congress B001230 Sen. Baldwin, Tammy [D-WI] Tammy Baldwin D WI N M000303 Sen. McCain, John [R-AZ] JOHN MCCAIN R AZ SIDNEY 2016-09-15 True A000368 Sen. Ayotte, Kelly [R-NH] Kelly Ayotte R NH 2016-09-19 False D000563 Sen. Durbin, Richard J. [D-IL] Richard Durbin D IL J. 2016-09-19 False Health Civil actions and liability Congressional oversight Consumer affairs Corporate finance and management Government information and archives Government studies and investigations Inflation and prices Medical research Prescription drugs Research and development Health 00 2016-09-15 Introduced in Senate 2016-09-29T11:40:12Z Fair Accountability and Innovative Research Drug Pricing Act of 2016

This bill amends the Public Health Service Act to require manufacturers of certain drugs and biological products to report to the Department of Health and Human Services (HHS) price increases that result in a 10% or more increase in the price of a drug over a 12-month period. Reports are required for prescription drugs and drugs commonly administered in hospitals, except vaccines, drugs for rare conditions, and drugs with annual sales for Medicare and Medicaid enrollees of less than $1.

Manufacturers that do not submit a required report are subject to a civil penalty. The Inspector General of HHS must review drug price information to determine compliance. Collected penalty funds must be used to carry out activities related to this reporting requirement and to improve consumer and provider information about drug value and drug price transparency.

HHS must publish manufacturer reports, a summary of those reports, and supporting analyses.]]> Fair Accountability and Innovative Research Drug Pricing Act of 2016 Display Title Fair Accountability and Innovative Research Drug Pricing Act of 2016 Short Titles as Introduced Fair Accountability and Innovative Research Drug Pricing Act of 2016 Official Title as Introduced A bill to require reporting regarding certain drug price increases, and for other purposes. Introduced in Senate 2016-09-15T04:00:00Z https://www.govinfo.gov/content/pkg/BILLS-114s3335is/xml/BILLS-114s3335is.xml 2016-09-15 Read twice and referred to the Committee on Health, Education, Labor, and Pensions. text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain. Congressional Research Service, Library of Congress This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.